Our Website Uses Cookies 


We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.


For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Secures Key Preliminary Injunction for Indivior

July 13, 2018

WASHINGTONCovington's patent litigators secured a significant win on behalf of Indivior, obtaining a preliminary injunction preventing Dr. Reddy's Laboratories from launching a generic version of Indivior's SUBOXONE®  Sublingual Film used in treatment of opioid addiction. The court's decision recognizes that Indivior had shown a likelihood of success on the merits and that it would be irreparably harmed in the absence of injunctive relief.

Indivior is a global pharmaceutical company focused on treatment of addiction and its co-occurring disorders, and SUBOXONE® Film currently accounts for the majority of its revenue. After Dr. Reddy's generic launch, obtaining an injunction and protecting Indivior's intellectual property rights were critical to Indivior's business. Indivior is the exclusive licensee of the patent at issue in the injunction, U.S. Patent No. 9,931,305, which issued earlier this year.

The Covington team was led by Jeffrey Elikan and Jeffrey Lerner, and included Jason Fowler, Erica Andersen, Matthew Kudzin, Isaac Belfer, Ashley Kwon, Philip May, Hannah Jiam, and Robert Zhou.

Share this article: